StockData
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc. (OVID) stock

OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.22−0.18 (-7.50%)

Close on Nov 17, 2026Market cap $433.56MP/E –Yield –

Ovid Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Ovid Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $33.60M, up 24.9% year over year. For fiscal 2025 it was $25.58M, down 30.4% from the year before. Over ten years it grew 14.5% a year on average. The highest annual figure on record is $63.42M in fiscal 2020.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$25.58M-30.4%
FY2024Dec 31, 2024$36.77M+28.6%
FY2023Dec 31, 2023$28.59M+16.1%
FY2022Dec 31, 2022$24.62M-47.6%
FY2021Dec 31, 2021$46.94M-26.0%
FY2020Dec 31, 2020$63.42M+50.4%
FY2019Dec 31, 2019$42.16M+24.8%
FY2018Dec 31, 2018$33.79M-32.4%
FY2017Dec 31, 2017$49.97M+421.3%
FY2016Dec 31, 2016$9.59M+45.0%
FY2015Dec 31, 2015$6.61M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$9.96M+54.0%
Q1 FY2026Mar 31, 2026$11.18M+67.9%
Q4 FY2025Dec 31, 2025$6.59M+11.2%
Q3 FY2025Sep 30, 2025$5.87M-25.3%
Q2 FY2025Jun 30, 2025$6.47M-48.6%
Q1 FY2025Mar 31, 2025$6.66M-36.0%
Q4 FY2024Dec 31, 2024$5.92M-44.3%
Q3 FY2024Sep 30, 2024$7.86M+47.3%
Q2 FY2024Jun 30, 2024$12.58M+109.7%
Q1 FY2024Mar 31, 2024$10.40M+57.2%
Q4 FY2023Dec 31, 2023$10.64M+91.5%
Q3 FY2023Sep 30, 2023$5.33M+2.9%
Q2 FY2023Jun 30, 2023$6.00M-0.8%
Q1 FY2023Mar 31, 2023$6.62M-15.5%
Q4 FY2022Dec 31, 2022$5.56M-69.3%
Q3 FY2022Sep 30, 2022$5.18M+5.4%
Q2 FY2022Jun 30, 2022$6.05M-21.3%
Q1 FY2022Mar 31, 2022$7.83M-51.8%
Q4 FY2021Dec 31, 2021$18.09M+7.1%
Q3 FY2021Sep 30, 2021$4.92M-69.0%
Q2 FY2021Jun 30, 2021$7.68M-52.1%
Q1 FY2021Mar 31, 2021$16.25M+11.1%
Q4 FY2020Dec 31, 2020$16.88M+39.5%
Q3 FY2020Sep 30, 2020$15.88M+36.9%
Q2 FY2020Jun 30, 2020$16.03M+75.8%
Q1 FY2020Mar 31, 2020$14.63M+56.6%
Q4 FY2019Dec 31, 2019$12.11M+40.4%
Q3 FY2019Sep 30, 2019$11.60M+35.7%
Q2 FY2019Jun 30, 2019$9.12M+12.3%
Q1 FY2019Mar 31, 2019$9.34M+10.2%
Q4 FY2018Dec 31, 2018$8.62M+28.4%
Q3 FY2018Sep 30, 2018$8.54M+44.8%
Q2 FY2018Jun 30, 2018$8.12M+33.6%
Q1 FY2018Mar 31, 2018$8.47M-72.9%
Q4 FY2017Dec 31, 2017$6.71M+68.2%
Q3 FY2017Sep 30, 2017$5.90M+118.6%
Q2 FY2017Jun 30, 2017$6.07M–
Q1 FY2017Mar 31, 2017$31.28M–
Q4 FY2016Dec 31, 2016$3.99M–
Q3 FY2016Sep 30, 2016$2.70M–

More Ovid Therapeutics figures

See a number that looks wrong?